Jazz Pharmaceuticals (JAZZ) PT Cut to $170 at Canaccord Genuity

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/21/2026

1. INTC
2. DSX
3. GNK
4. DAL
5. AWK
6. SPCX
7. III
8. TTEC
9. SNY

Go back to Jazz Pharmaceuticals (JAZZ) PT Cut to $170 at Canaccord Genuity

Delays at the central pharmacy Negatively Hit Jazz Pharmaceuticals (JAZZ); Piper Jaffray Cuts Price Target to $186

November 10, 2015 9:51 AM EST

Piper Jaffray reiterated an Overweight rating on Jazz Pharmaceuticals (NASDAQ: JAZZ), and cut the price target to $186.00 (from $208.00), following the company's 3Q earnings report. Jazz reported non-GAAP EPS of $2.52 on revenues of $341M, largely in-line with the Street estimates of $2.56 and $348M, respectively. Xyrem sales totaled $243M, up from $204M in 3Q14, with annual volume... More

Jazz Pharmaceuticals (JAZZ) Reports Topline Miss Related to Delays in Xyrem Refills; Leerink Partners Cuts Price Target to $187

November 10, 2015 8:42 AM EST

Leerink Partners maintained an Outperform rating on Jazz Pharmaceuticals (NASDAQ: JAZZ), and cut the price target to $187.00 (from $220.00), following the company's 3Q earnings report. JAZZs update included a modest topline miss driven by slower patient volume growth as the company experienced delays in Xyrem refills.

Analyst Jason... More

Jazz Pharmaceuticals (JAZZ) Misses Q3 EPS by 4c, Updates FY Guidance

November 9, 2015 4:10 PM EST

Jazz Pharmaceuticals (NASDAQ: JAZZ) reported Q3 EPS of $2.52, $0.04 worse than the analyst estimate of $2.56. Revenue for the quarter came in at $340.9 million versus the consensus estimate of $348.15 million.

Jazz Pharmaceuticals sees FY2015 EPS of $9.45-$9.60, versus the consensus of $9.67. Jazz Pharmaceuticals sees FY2015... More